Outcomes for Women Receiving Bevacizumab for Treatment of Ovarian Cancer Versus Other Solid Tumors at an Academic Oncology Center  by Robison, Katina et al.
Original StudyOutcomes for Women Receiving Bevacizumab
for Treatment of Ovarian Cancer Versus Other
Solid Tumors at an Academic Oncology Center
Katina Robison,1 Courtney Olson,2 Bachir J. Sakr,1 Tina Rizack,1
Robert Legare,1 Ashley Stuckey,1 C.O. Granai,1 Don S. Dizon3
Abstract
Bevacizumab use has dramatically increased in solid tumors. This retrospective cohort study evaluated the
incidence of toxicities associated with bevacizumab use in women with ovarian cancer compared to other
solid tumors. Although there was no signiﬁcant difference in toxicities found, there was a trend toward more GI
perforations among ovarian cancer patients that received multiple prior lines of chemotherapy.
Background: The main objective of this study was to determine the incidence of severe toxicity associated with bev-
acizumab use in women with ovarian cancer compared with that in women with other solid tumors. Patients and
Methods: This retrospective cohort study was performed by evaluating women treated with single-agent or combi-
nation bevacizumab in the Program in Women’s Oncology between January 2004 and May 2009. Data was collected
from electronic and ofﬁce-based medical records. Toxicity was assessed according to the National Cancer Institute’s
Common Toxicity Criteria version 3.0 guidelines. A total of 103 women were treated with bevacizumab: 41 women
(40%) with ovarian cancer and 62 (60%) with other solid tumors. Results: There was no increase in the number of toxic
effects seen in patients treated for ovarian cancer versus other tumor types. However, GI perforations were seen in
7.3% of women with ovarian cancer, whereas none were seen in those treated for other cancers (P ¼ .06). More than 1
bevacizumab-related toxic effect (hazard ratio [HR], 2.74; 95% CI, 1.35-5.55) and treatment with bevacizumab after 3
prior lines of chemotherapy (HR, 2.44; 95% CI, 1.159-5.129) were associated with an increase in mortality in women
with ovarian cancer. We found no signiﬁcant difference in the incidence of bevacizumab-related toxicities when
comparing ovarian cancer to other cancers. However, ovarian cancer patients did appear to have a statistically
nonsigniﬁcant higher percentage of GI perforations. Conclusion: Further studies evaluating patient factors associated
with increased risk of toxicities may be warranted to assist with appropriate patient selection prior to bevacizumab use.
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Angiogenesis is vital for cancer cell proliferation and metastasis,
and vascular endothelial growth factor (VEGF) is an important
regulator of this process. Bevacizumab is a recombinant humanized
monoclonal antibody directed against VEGF that demonstrates
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http://dx.doi.org/10.1016/j.cogc.2013.12.004properties of human VEGF.1 Bevacizumab is a molecularly targeted
therapy that is approved by the United States Food and Drug
Administration for treatment of several solid tumors, including
colorectal and nonesmall-cell lung cancers.2 Early phase II trials2-4
showed sufﬁcient single-agent activity to prompt combination trials.
Multiple randomized control trials have recently been published,
demonstrating bevacizumab efﬁcacy in ovarian cancer.5-7 However,
bevacizumab has been associated with serious adverse events,
including hypertension, venous thromboembolism, gastrointestinal
(GI) perforation, and death.5-7 In ovarian cancerespeciﬁc studies,
the risk of GI perforation, speciﬁcally, has ranged between 0% and
12%.4,6 Still, there has been no demonstrable difference in toxicity
incidence across tumor types.8
The National Comprehensive Cancer Network (NCCN) currently
recommends (category 3) the use of bevacizumab as frontline therapyClinical Ovarian and Other Gynecologic Cancer December 2013 - 21
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22 -in ovarian cancer with paclitaxel and carboplatin followed by bev-
acizumab maintenance for at least 12 months. Additionally, the
NCCN recommends (category 2A) bevacizumab in the recurrent
setting as a single agent, and bevacizumab has common off-label
use. Given its more frequent use, additional data is needed to
more accurately assess risks and beneﬁts of bevacizumab use in
ovarian cancer in routine academic practice outside of clinical trial
setting.9 The goal of this study was to determine the incidence of
severe toxicity associated with bevacizumab use in women with
ovarian cancer versus that in women with other solid tumors.
Materials and Methods
After receiving approval from the Women and Infants’ Hospital
of Rhode Island institutional review board, we conducted a retro-
spective cohort study of all women treated with single-agent or
combination bevacizumab in the Program in Women’s Oncology
between January 2004 and May 2009. The Program in Women’s
Oncology specializes primarily in gynecologic and breast cancers,
with over 24,000 patient visits per year. Data were collected from
electronic medical records and ofﬁce-based medical records. There
were no exclusion criteria. Only women who were aware that they
were being treated with bevacizumab were included in the study.
There were no patients included on placebo treatment. Toxicity was
assessed according to the National Cancer Institute’s Common
Toxicity Criteria version 3.0 guidelines. Statistical analyses per-
formed using MedCalc and JMP software. All categorical data was
compared using the c2 or Fisher exact test, and continuous data
were analyzed using descriptive statistics.
Results
Patient Characteristics
In all, 103 patients were treated with bevacizumab as a single agent
or as part of combination therapy. The demographic characteristics of
the cohort are given in Table 1. The median patient age was 54 years
(range, 18-85 years). Of the 103 patients, 41 women (40%) had
ovarian cancer, 34 (33%) had breast cancer, 24 (23%) had GI can-
cers, 3 (3%) had cervical cancer, and 1 (1%) had lung cancer. The
median number of chemotherapy regimens used prior to bevacizumabTable 1 Patient Demographics and Disease Characteristics
Characteristic Median Percent or (Range)
Age, years 54 (18-85)
BMI 24.5 (15.5-49.3)
Gravida, n 2 (0-9)
Cancer type
Ovarian, no. of patients 41 40
Breast, no. of patients 34 33
GI tract, no. of patients 24 23
Cervix, no. of patients 3 3
Lung, no. of patients 1 1
Prior chemotherapy regimens, n 2 (0-7)
Bevacizumab cycles, n 9 (1-83)
Abbreviations: BMI ¼ body mass index; GI ¼ gastrointestinal.
Clinical Ovarian and Other Gynecologic Cancer December 2013was 2 (range, 0-7); prior chemotherapy regimens varied based on
tumor type. The patients received a median of 9 total cycles of bev-
acizumab, with 1 patient receiving as many as 83 cycles (range, 1-83).
Toxicity
The median number of bevacizumab-related serious (grade 3
or 4) toxic effects per patient was 1 (range, 0-5). There was no
increase in the number of toxic effects seen in patients treated for
ovarian cancer versus those treated for other tumor types. However,
GI complications were more common in women with ovarian
cancer than in those with other tumors. GI perforations were seen in
7.3% of women with ovarian cancer, while none were seen in those
treated for other cancers (P ¼ .06). Similarly, obstruction was noted
in 12% of women with ovarian cancer and 3.2% of those with other
tumors (P ¼ .07)(Table 2). These toxicities are not commonly
associated with the prior chemotherapies received by ovarian cancer
patients in this study, including: paclitaxel, carboplatin, liposomal
doxorubicin, gemcitabine, topotecan, etoposide, and docetaxel. All
but one of these patients with bowel obstruction had evidence of
disease recurrence at the time of bowel obstruction diagnosis. Other
common toxic effects seen in women with ovarian cancer versus
other types of tumors were grade 3 or 4 hypertension (48% vs.
40%, respectively) and bowel obstruction (12%), though neither
occurred signiﬁcantly more frequently than in other cancer types.
We were unable to determine the number of women who had
preexisting hypertension. Additional severe toxicities included
myocardial infarction (2% in ovarian cancer patients vs. 1% in
patients with other tumor types) and stroke (0% in ovarian cancer
patients vs. 3.2% in patients with other tumor types) among pa-
tients treated with bevacizumab.
A multiple regression analysis was performed to identify factors
associated with mortality in the cohort. Documentation of moreHypertension
Grade 3 23 (37.1) 19 (46.3) .11
Grade 4 2 (3.2) 1 (2.4) .44
Gastrointestinal
Bowel obstruction 2 (3.2) 5 (12) .07
Bowel perforation 0 (0) 3 (7.3) .06
Nausea/vomiting 11 (17.7) 8 (19.5) .20
Liver-related 2 (3.2) 0 (0) .40
Fistula formation 1 (1.6) 1 (2.4) .48
Vascular
Bleeding 2 (3.2) 2 (4.9) .35
Thrombosis 4 (6.5) 1 (2.4) .26
Ischemia
Myocardial infarction 1 (1.6) 1 (2.4) .48
Stroke 2 (3.2) 0 (0) .36
Wound-healing
complication
0 (0) 1 (2.4) .40
Katina Robison et althan 1 bevacizumab-related toxic effect (HR, 2.74; 95% CI, 1.35-
5.55) and treatment with bevacizumab after 3 prior lines of
chemotherapy (HR, 2.44; 95% CI, 1.60-5.13) were associated with
an increase in mortality on bevacizumab treatment. However, we
were unable to identify any signiﬁcant association between
treatment-related factors and GI perforations. Still, review of the
data demonstrates that all 3 patients with GI perforations received at
least 3 prior regimens of chemotherapy; the median number of prior
regimens in patients with GI perforations was 5 compared with 2
for the entire cohort.
Discussion
During the past decade, the use of bevacizumab in the treatment
of cancers ranging from pediatric low-grade tumors10 to metastatic
colorectal cancer has been promising.11 The antiangiogenicmechanism
has sparked an interest in using bevacizumab for other diseases, such as
retinal neovascular diseases.12,13 However, the role of bevacizumab in
cancer therapy remains at the forefront of investigation.
Multiple randomized control trials have shown bevacizumab
prolongs progression-free survival and improves recurrence rates in
frontline ovarian cancer. However, none has yet to show bev-
acizumab improves overall survival. In addition, these studies have
suggested a higher rate of hypertension and proteinuria in ovarian
cancer patients exposed to bevacizumab, which is consistent with
the ﬁndings in other solid tumors.8,10 Still, off-label use is wide-
spread among providers who treat ovarian cancer, despite concerns
about adverse risk-beneﬁt ratio. Hence, we chose to look at our
experience with bevacizumab in both ovarian and nonovarian cancer
indications, particularly because, as a women’s oncology program,
we have a population that could aid in addressing this issue. Our
ﬁndings indicate there is no statistically signiﬁcant difference in the
incidence of bevacizumab-related toxicity between patients with
ovarian cancer and those with other solid tumors. Still, a trend to-
ward increased risk of GI complications is noted. Risk factors for GI
perforation include extensive tumor bowel involvement and preex-
isting bowel wall inﬂammation.6 Ovarian cancer patients may be at
a higher risk of GI perforation with VEGF inhibition compared
with that of patients with other cancer types because they are prone
to bowel dysmotility and subacute bowel obstruction secondary to
the pathophysiology of the disease.14 Simpkins et al. recommended
a careful selection process for bevacizumab use in ovarian cancer by
excluding those with clinical symptoms of bowel obstruction or
clinical or radiologic evidence of tumor bowel involvement.1 This
screening process could be used to identify patients at high risk of
GI perforation until further studies elucidate the mechanism of GI
complications in ovarian cancer patients treated with bevacizumab.
For women who received bevacizumab, risks associated with
death included a prior history of  3 cytotoxic regimens and the
occurrence of more than 1 bevacizumab-related toxic effect. The
incidence of GI perforation was consistent with the range of 0%
to 12% found in phase II and III trials.2-4,6,7 All 3 patients with GI
perforations received  3 cytotoxic regimens. It has been suggested
that earlier use of bevacizumab may be better tolerated and have less
risk of GI perforation. Penson et al. recently investigated the use of
bevacizumab as part of a combination chemotherapy regimen for
newly diagnosed ovarian cancer and found a GI perforation rate of
only 3%.15 The safest time for incorporating bevacizumab may beearlier in the treatment of ovarian cancer.15,16 Determination of the
optimal regimen will require further prospective studies.
Conclusion
In conclusion, although bevacizumab demonstrates promising
clinical activity in the treatment of several cancer types, the toxicity
proﬁle of this biologic agent is not yet fully characterized. We
found no signiﬁcant difference in the incidence of bevacizumab-
related toxicities when comparing ovarian cancer to other cancers.
Ovarian cancer patients treated with bevacizumab did appear to
have a higher percentage of GI perforations, but this association did
not reach statistical signiﬁcance. It appears that in women with
ovarian cancer, the risk of bowel perforation with bevacizumab
therapy may be minimized by optimal selection of patients.
Women with at least 1 severe toxicity and who had  3 lines of
chemotherapy had increased mortality with bevacizumab treat-
ment. Further prospective studies are warranted to determine the
optimal timing of bevacizumab administration in cancer patients
and to identify mechanisms for severe toxicities, including GI
perforation.
Clinical Practice Points
 Bevacizumab has demonstrated promising clinical activity in
multiple solid tumors including ovarian cancer.
 Our study suggests certain patients are more likely to experience
bowel related toxicities.
 Future research examining how prior cycles of chemotherapy
impact bowel toxicity is needed.
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